Nurix Therapeutics (NASDAQ:NRIX) Bolsa, Quote.MetaTitle.unusual-options

Nurix Therapeutics

Nurix Therapeutics Inc

Ardelyx

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CureVac

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immunome

Immatics

Inhibrx Biosciences

MiMedx Group

NuCana

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Relay Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

UroGen Pharma

Zymeworks

Nurix Therapeutics (NRIX) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Comments

Nurix Therapeutics Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL